5 results about "Allergic contact dermatitis" patented technology

Methods and items useful at least therein are provided for IBS related testing and treatment. Disclosed is a patch useful in determining if one or more test materials can cause allergic contact dermatitis in a patient. A kit containing information on use and that may include such a patch and / or test material(s) is also disclosed. A method of IBS related testing including performing skin patch testing on a patient presenting IBS symptoms using at least one test material that can cause allergic contact dermatitis is provided. A method for the treatment of IBS which includes limiting the intake by a patient presenting IBS symptoms of at least one material that gives a positive skin patch test result in the patient is also disclosed.

This invention discloses a method for preparing an aqueous extract of Artemisia argyi and its application, particularly in the preparation of drugs for treating allergic contact dermatitis. The preparation method includes step 1: naturally air-drying harvested Artemisia argyi leaves, followed by mechanical pulverization to obtain Artemisia floss raw material; step 2: mixing the Artemisia floss raw material with pure water, soaking at room temperature, extracting with ultrasound assistance, combining the extracts, decocting in a water bath, concentrating under reduced pressure, and freeze-drying to obtain the Artemisia argyi aqueous extract. This invention provides an Artemisia argyi aqueous extract, its preparation method, and its application. This Artemisia argyi aqueous extract has significant anti-allergic and anti-irritant effects, effectively inhibiting hyaluronidase activity, reducing erythrocyte hemolysis rate, and exhibiting good therapeutic effects on 2,4-dinitrofluorobenzene-induced allergic contact dermatitis. It also has high bioavailability and good safety. This invention lays an important foundation for developing efficient and safe natural anti-allergic products.

The invention belongs to the technical field of biological medicines, discloses an application of secreting type glucose regulatory protein 78 in preparation of a medicine for treating allergic contact dermatitis, and proves that the secreting type Grp78 protein reduces inflammatory reaction by inducing macrophage M2 polarization and reducing expression of cytokines IL-6, INF-gamma and TNF-alpha, so that symptoms of ACD are improved, and the application of the secreting type Grp78 protein in preparation of the medicine for treating allergic contact dermatitis is promoted. And a new theoretical basis and a new technical method are provided for treatment of ACD and exploration of novel drugs.

This application discloses the use of neuroprotective agent D1 (NPD1) in the preparation of drugs to relieve / treat chronic pruritus, relating to the field of biomedical technology. This invention provides NPD1 that can reverse spinal cord demyelination and relieve chronic pruritus. NPD1 can be used to relieve and / or treat chronic dermatitis pruritus, particularly showing excellent inhibitory effects against allergic contact dermatitis. The NPD1 can be developed into conventional lipid nanoparticles (LNPs) or other similar lipid nanoparticle drug formulations for drug delivery, possessing significant potential application value for relieving itching. The NPD1 developed in this invention can directly relieve pruritus abnormalities caused by dorsal horn demyelination of the mouse spinal cord, fundamentally inhibiting the occurrence of pruritus abnormalities in chronic dermatitis, solving the clinical problem of chronic pruritus that plagues patients with chronic dermatitis, and providing a new and effective solution for the clinical treatment of chronic dermatitis, especially pruritus in allergic contact dermatitis.

The invention relates to an application of a traditional Chinese medicine composition in preparing a medicine for treating allergic contact dermatitis, which is characterized in that the traditional Chinese medicine composition is prepared from astragalus membranaceus, dried ginger, salted morinda officinalis, cortex dictamni, calcined oyster shell, schisandra chinensis and divaricate saposhnikovia root. The composition disclosed by the invention can be used for remarkably inhibiting ear swelling of allergic contact model mice, remarkably reducing the content of IL-5 and IL-9 in ear tissues of the model mice and remarkably reducing the spleen index of the model mice, and has a relatively good treatment effect on the allergic contact dermatitis.